Universe Pharmaceuticals faces a structural decline in its core distribution business, evidenced by a 14.1% year-over-year revenue contraction in 2025Q4.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
Universe Pharmaceuticals INC (NASDAQ: UPC - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.88 and traded as low as $2.85. Universe Pharmaceuticals shares last traded at $2.88, with a volume of 188,197 shares changing hands. Wall Street Analyst Weigh In
Universe Pharmaceuticals INC (NASDAQ: UPC - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 75,844 shares, an increase of 154.7% from the August 31st total of 29,772 shares. Approximately 3.5% of the company's shares are short sold.
Benchmark UPC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Universe Pharmaceuticals Inc. (UPC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.39 | $783.04K | -0.00 | -22.44% | -20.56% | -7.23% | — | |
| $1.02 | $354.59K | -0.07 | -97.89% | -73.22% | -142.16% | — | |
| $1.55 | $682.16K | -0.10 | -100% | — | — | — | |
| $4.16 | $1.44B | -10.77 | 698.96% | -67.38% | -49.11% | — | |
| $1.05 | $54.49M | -5.26 | — | -1507600% | -87.28% | — | |
| $3.10 | $222.34M | -80.94 | -31.8% | -5.14% | -1.53% | 19.42% |
Universe Pharmaceuticals Inc. (UPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when UPC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Universe Pharmaceuticals Inc. (UPC) stock FAQ — growth, dividends, profitability & financials explained
Universe Pharmaceuticals Inc. (UPC) reported $17.9M in revenue in fiscal year 2025. That is 37% less than the $28.5M of fiscal year 2018.
Universe Pharmaceuticals Inc. (UPC) revenue fell by 22.4% in fiscal year 2025, compared with the prior fiscal year.
No. Universe Pharmaceuticals Inc. (UPC) reported a net loss of $3.7M in fiscal year 2025.
Universe Pharmaceuticals Inc. (UPC) had a return on equity (ROE) of -7.2% in fiscal year 2025. A negative ROE means the company lost money over the period.
Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $5.4M in fiscal year 2025.
